With the help of our sophisticated in-house facilities and technology, we can offer a range of high effective Ribociclib. Ribociclib CAS 1211441-98-3, also called LEE011, CDK4/6 Inhibitor and CDK4 Inhibitor which is a a potent cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. LEE011 CAS NO 1211441-98-3 shows to reduce proliferation in 12 of 17 human neuroblastoma-derived cell lines by inducing cytostasis (mean IC₅₀ = 306 nM in sensitive lines. And CDK4 Inhibitor 1211441-98-3 is most commonly used to treat patients with breast cancer. Customers can take use of these features as per their needs.

Thera. Category: CDK4/6 Inhibitor

Cas No.: 1211441-98-3

Synonym:7-Cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide;7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide;7-Cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide LEE 011;LEE 011 7-Cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide

Molecular Formula:C23H30N8O

Molecular Weight:434.5373

Assay: ≥99.%

Packing: Export worthy packing

lMaterial Safety Data Sheet: Available on request

Usage: Ribociclib is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.